Acorda Therapeutics (ACOR) Tops Q4 EPS by 25c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
February 13, 2020 7:00 AM EST2020 Guidance:
Total net product revenue expected to be $120 - $150 million INBRIJA® (levodopa inhalation powder) net revenue expected to be $35 - $40 million INBRIJA peak sales revised to $300 - $500 million AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg. net revenue expected to be $85 - $110 millionARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the fourth quarter and full year ended December 31, 2019.
INBRIJAs launch was an important milestone for... More
